NEXTCLINICS CONTINUES GROWING, THE GROUP ACQUIRED PROMINENT ASSISTED REPRODUCTION CLINICS IN NORTHERN ITALY
Bologna/Augsburg, 17 July 2018: In late June 2018, NEXTCLINICS acquired 100% of GynePro, an Italian medical Group with in-vitro fertilization (IVF) clinics located in Bologna and Verona. With a 20 year history, GynePro is a highly experienced and renowned medical group active in the area of infertility management, assisted reproductive technology (ART), and prenatal diagnosis. GynePro’s founder, Professor Dr. Marco Filicori, will remain with the clinic as its Medical Director and will become a shareholder and investor in NEXTCLINICS. This transaction strengthens NEXTCLINICS’ position as a leading pan European provider of ART clinics and laboratories. This is NEXTCLINICS’ first major transaction in 2018, and follows a number of late 2017 investments in leading fertility centers and laboratories across Europe, valued at 80 million Euro. The valuation of the GynePro transaction will not be disclosed.17.07.2018 | More >
NEXTCLINICS’s top doctors and experts from ProCrea, Gest and IMER participated in ESHRE (European Society of Human Reproduction and Embryology) in early July 2018.04.07.2018 | More >
Accompanied by the charming atmosphere of the romantic castle of Hluboká a Zámecká jízdárna (Chateau Riding School), more than 150 employees and friends of NEXTCLINICS attended the NEXTCLINICS DAY event on June 15 and 16. The event included a splendid program and provided a lot of new news about the company’s dynamic growth.20.06.2018 | More >
NEXTCLINICS, a provider of premium health care services and a leader in smart health, has over the last three months enjoyed dynamic growth and evolution. The company has gone through significant changes, all leading to building a stable brand that represents quality health care with high value-added services including interactive communication between the patient and the health care facility.07.06.2018 | More >
ProCrea Lugano has announced a new "Open Door Evening" which will take place Thursday 17th of May 2018 at 6 p.m. Treatment and support in infertility in the “Open Door Evening” of ProCrea.04.05.2018 | More >
Continual company expansion has meant the requirement for more space, therefore the decidion to relocate NEXTCLINICS Czech a.s. was taken. Since 16th April 2018 we can be found at the famous Prague TOKOVO building (Jankovcova 1518/2, 170 00, Prague 7, 7th floor).
Billing address is still the same.
Continuing dynamic development of NL-Holding brings another important change. The Czech subsidiary of NL-Holding comprising of the three constituent parts (clinics, laboratories, and Next Life project) was renamed. The name of NL-Holding a.s. was replaced by NEXTCLINICS Czech a.s.04.04.2018 | More >
On 31st March 2018, the long-term cooperation between major healthcare providers Poliklinika Anděl s.r.o., RESPIMED s.r.o. and NEXT CLINICS group resulted in further synergy.29.03.2018 | More >
On the 26th of February 2018 a workshop concerning Women's Health and Genetics was held under the auspices of the University of Pittsburgh and we participated.19.03.2018 | More >
The aim of the 2nd Lugano Advances Training in Reproductive Medicine is to enlighten participants on innovations that affect how we handle oocytes, embryos and the uterus.27.02.2018 | More >
NL Holding announces it has secured Oaktree Capital Management, a major global investment group, as its partner for further expansion and the acquisition of healthcare facilities in Spain, Italy, and Switzerland.
Augsburg, 14 February 2018: At the end of 2017, NL Holding, a dynamically growing European healthcare company headquartered in Augsburg, secured an investment by Oaktree Capital Management, one of the world’s largest investment groups. Today, NL Holding announces it continued to realize its investment plans with new acquisitions of healthcare facilities in Spain (IMER), Italy (Archimed Group) and Switzerland (ProCrea Group in Lugano). NL Holding has already invested 80 million Euro to date and intends to invest up to 200 million Euro in 2018. The amount of the Oaktree investment will not be disclosed.15.02.2018 | More >
NL-HOLDING MAKES A MAJOR ACQUISITION TO STRENGTHEN ITS POSITION ON THE REPRODUCTIVE IMMUNOLOGY AND CLINICAL GENETICS MARKET
Medical company NL-Holding has acquired Genetika Plzeň, a clinical genetics company based in the town of Pilsen, West Bohemia, with has offices in Pilsen and Karlovy Vary and operates a cytogenetic molecular laboratory and a reproductive immunology laboratory.04.09.2017 | More >